Nivo-lution in mesothelioma.

Nivo-lution in mesothelioma.
Clin Cancer Res. 2019 Jul 17;:
Authors: Mansfield AS, Zauderer MG
Abstract
The MERIT study was a single-arm, phase 2 clinical trial of nivolumab for the 2nd or 3rd line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
PMID: 31315884 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 16, 2019 Category: Cancer & Oncology Authors: Mansfield AS, Zauderer MG Tags: Clin Cancer Res Source Type: research